

**Prof Jarrod Homer** ([www.jarrodhomer.co.uk](http://www.jarrodhomer.co.uk))

Consultant Otolaryngologist-Head and Neck Surgeon - Manchester  
Royal Infirmary  
Honorary Clinical Professor - University of Manchester

ENT Cancer National lead, GIRFT/National Cancer Program, NHS Eng  
(Partial secondment)



Professor Jarrod Homer is a consultant surgeon at The Manchester Head and Neck Centre, Manchester University Foundation NHS Trust and also has a chair in Otolaryngology-Head and Neck Surgery at The University of Manchester.

He completed higher surgical training, sub-specialty H&N surgical oncology training and a research fellowship in head and neck cancer leading to a doctorate degree. He was appointed to his consultant post in 2002 at Manchester Royal Infirmary and Christie Hospital in 2002, with academic promotion to Professor in 2013.

His clinical practice encompasses all of head and neck /thyroid cancer, with a particular interest in conservation laryngeal surgery, sinonasal and antero-lateral skull base cancers. He introduced surgeon performed neck ultrasound scanning in 2003 and runs an international course in neck ultrasound. He is editor of the current (6th Edition -2023) UK Multidisciplinary Guidelines for Head and Neck Cancer. He has published >100 research papers and has supervised several MD/PhD's in H&N cancer." "This is an area of genuine unmet need in H&N oncology. Surgery alone (at least for high grade cancers) is usually insufficient and there is a need for effective systemic individualised therapies.

In the past we evaluated STI 571 (glivec)a potent inhibitor of c-kit in adenoid cystic carcinoma (Bruce et al 2005) leading to a clinical trial (Ghosal et al 2011). I work currently with Dr Rob Metcalf and Dr Guy Betts in Manchester and so have good links with their research. Although this is generally non-surgical, I have plenty of research expertise in biomarkers (many of my supervised MD's were in this area) and can assist and contribute as an academic surgeon. One area to carefully consider is how systemic therapies intertwine with surgery (both in terms of timing/sequencing and selection of modality), and to consider when surgery works well and when it causes potentially more harm than benefit.

Prof Homer has a clinical and research interest in anterior skull base/ sinonasal cancers, with many common areas (some of which are salivary gland tumour types).

**Notable current editorships:**

Chief Editor, UK Head and Neck Cancer Multidisciplinary Guidelines. Publication date 2023.

**Current Clinical Trials**

I am part of the Trial Management group for the following clinical trials:

TORPEO (phase III trial of intensity-modulated proton beam therapy vs intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer)

PROTIS (phase 3 trial of Proton Beam Therapy vs IMRT in Sinonasal Cancer) (also co-investigator)

Principle Investigator:PATHOS (NCRI) (de-escalation of postsurgical therapy in HPV positive oropharyngeal cancers- open (17 recruited)